South Korea approves homegrown COVID-19 vaccine for booster shots | Inquirer News

South Korea approves homegrown COVID-19 vaccine for booster shots

/ 03:58 PM September 18, 2022

This photo provided by SK Bioscience Co. shows GBP510, South Korea’s first COVID-19 vaccine candidate also known as SKYCovione. (SK Bioscience Co. via The Korea Herald/Asia News Network)

SEOUL — South Korea on Friday authorized the use of SKYCovione, a homegrown COVID-19 vaccine developed by SK Bioscience Co., for booster shots against the coronavirus in addition to its use as primary inoculations.

The decision was announced by Second Vice Health Minister Lee Ki-il at the meeting of the government’s Central Disaster and Safety Countermeasure Headquarters.


Hospitals and clinics will be allowed to administer SKYCovione vaccines as third and fourth inoculations from Sept. 26.

The state-run Center for Infectious Disease Research said earlier this month it has confirmed SKYCovione’s efficacy in neutralizing the BA.1 and BA.5 coronavirus omicron subvariants when used after two prior vaccine jabs.


When inoculated with SKYCovione as a booster shot, the virus neutralizing effect was 51.9 times higher against the BA.1 subvariant and 28.2 times higher against the BA.5 subvariant, the center said.

SKYCovione is a recombinant-protein vaccine based on novel two-component nanoparticles that can maximize the immune effect. It was jointly developed with the Institute for Protein Design at the University of Washington.


South Korea’s 1st domestic COVID-19 vaccine ready

South Korea approves first domestically developed COVID-19 vaccine

Read Next
Don't miss out on the latest news and information.

Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer & other 70+ titles, share up to 5 gadgets, listen to the news, download as early as 4am & share articles on social media. Call 896 6000.

TAGS: COVID-19 Vaccines, Health, South korea
For feedback, complaints, or inquiries, contact us.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2022 | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.